Page last updated: 2024-12-05

1,4-androstadiene-3,17-dione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,4-androstadiene-3,17-dione is a **steroid hormone precursor** that plays a crucial role in the synthesis of various important steroid hormones, including **testosterone** and **estradiol**. It is also known as **androstenedione**.

**Here's why it's important for research:**

* **Understanding Steroid Hormone Synthesis:** Researchers use androstenedione to study the pathways involved in steroid hormone production. By manipulating its levels or studying its interactions with enzymes involved in steroidogenesis, researchers can gain valuable insights into the regulation of hormone production.
* **Developing New Therapies:** Androstenedione's role as a precursor to both testosterone and estradiol makes it a potential target for developing new therapies for conditions related to hormone deficiencies or imbalances. For example, it may be explored for potential applications in treating hypogonadism, menopause, and other hormone-related disorders.
* **Studying Steroid Hormone Effects:** Researchers use androstenedione to investigate the effects of different steroid hormones on various biological processes. This can help us understand the role of these hormones in development, metabolism, reproduction, and other vital functions.
* **Investigating Drug Interactions:** Androstenedione may be used to study the interactions between various drugs and steroid hormone pathways. This information is crucial for understanding potential side effects of drugs and for developing more targeted and effective drug therapies.

**However, it's important to note:**

* **Potential for Abuse:** Androstenedione has been marketed as a dietary supplement for athletes seeking to boost testosterone levels. However, its use as a performance-enhancing drug is controversial and can lead to health risks.
* **Regulation:** Androstenedione is a controlled substance in many countries due to its potential for misuse.

Overall, 1,4-androstadiene-3,17-dione is a valuable tool for research, providing researchers with a means to delve into the intricate world of steroid hormone synthesis, regulation, and function. While it holds promise for therapeutic development, its use must be carefully monitored and regulated due to its potential for misuse.

1,4-androstadiene-3,17-dione: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

androsta-1,4-diene-3,17-dione : A steroid that consists of androstane having double bonds at positions 1 and 4 and two keto groups at positions 3 and 17. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13472
CHEMBL ID1078534
CHEBI ID40799
SCHEMBL ID134061
MeSH IDM0049191

Synonyms (53)

Synonym
smr000112159
MLS002207247
2166q8568w ,
ec 212-977-2
unii-2166q8568w
boldione
nsc 49080
einecs 212-977-2
androstadienedione
897-06-3
1-dehydroandrostenedione
nsc-49080
ANB ,
androsta-1,4-diene-3,17-dione
10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-6h-cyclopenta[a]phenanthrene-3,17-dione
1,4-androstadiene-3,17-dione
1H62
DB07373
(8r,9s,10r,13s,14s)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione
chebi:40799 ,
CHEMBL1078534
androstenedone
STK801872
A843288
AKOS005622723
C20144
A0856
androst-1,4-dien-3,17-dione, 7
bdbm91718
testosterone impurity g [ep impurity]
(+)-androsta-1,4-diene-3,17-dione
j38.935h ,
exemestane impurity d [ep impurity]
androstane-1,4-diene-3,17-dione
.delta.1,4-androstadiene-3,17-dione
androsta-1,4-dien-3,17-dione
BBL033692
SCHEMBL134061
1,4-androstadien-3,17-dione
W-100363
androstra-1,4-diene-3,17-dione
(1s,2r,10r,11s,15s)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,14-dione
androsta-1,4-diene-3, 17-dione
androstane-1,4-diene-3, 17-dione
androsta-1,4-diene-3,17-dione (androstadienedione)
(8alpha,14beta)-androsta-1,4-diene-3,17-dione
DTXSID00862463
Q4939115
(3as,3br,9ar,9bs,11as)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,7h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthrene-1,7-dione
VS-12222
testosterone ep impurity g
BCP28281
(8r,10r,13s)-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-6h-cyclopenta[a]phenanthrene-3,17-dione

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Boldione and its three metabolites were detected in dosed human urine after dosing a healthy volunteer with 100 mg boldione."( Characterization of boldione and its metabolites in human urine by liquid chromatography/electrospray ionization mass spectrometry and gas chromatography/mass spectrometry.
Jun, M; Kim, Y; Lee, W, 2006
)
0.33
" The treatments after dosing P4 exhibited a shorter time than the control group until half of the initial P4 inclusion was eliminated (i."( Diurnal variations of progesterone, testosterone, and androsta-1,4-diene-3,17-dione in the rumen and in vitro progesterone transformation by mixed rumen microorganisms of lactating dairy cows.
Li, SL; Ren, QC; Wang, JQ; Yang, HJ, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
17-oxo steroidAny oxo steroid carrying the oxo group at position 17.
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
3-oxo-Delta(1) steroidAny 3-oxo steroid that contains a double bond between positions 1 and 2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
superpathway of cholesterol degradation II (cholesterol dehydrogenase)3058
superpathway of cholesterol degradation I (cholesterol oxidase)1755
androstenedione degradation3439
superpathway of testosterone and androsterone degradation1136

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency22.72650.000811.382244.6684AID686978; AID686979
chromobox protein homolog 1Homo sapiens (human)Potency56.23410.006026.168889.1251AID540317
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency125.89206.309660.2008112.2020AID720707
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CholinesteraseHomo sapiens (human)IC50 (µMol)102.66000.00001.559910.0000AID1799735
AromataseHomo sapiens (human)IC50 (µMol)0.41500.00001.290410.0000AID53557
AromataseHomo sapiens (human)Ki0.32580.00000.60469.5010AID1270833; AID53739; AID53744; AID53869; AID53884; AID54048
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Pentaerythritol Tetranitrate ReductaseEnterobacter cloacaeKd17.000017.000017.000017.0000AID977611
Chain A, Pentaerythritol Tetranitrate ReductaseEnterobacter cloacaeKd17.000017.000017.000017.0000AID977611
Chain A, PENTAERYTHRITOL TETRANITRATE REDUCTASEEnterobacter cloacaeKd17.000017.000017.000017.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AromataseHomo sapiens (human)Km0.39000.02000.13240.7600AID53898; AID53902
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (47)

Processvia Protein(s)Taxonomy
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID53557In vitro inhibitory activity against Cytochrome P450 19A1 in human placental microsomes1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Time-dependent inactivation of aromatase by 6-alkylandrosta-1,4-diene-3,17-diones. Effects of length and configuration of 6-alkyl group.
AID18771Limiting t1/2 is the half life of aromatase inactivation in the presence of saturating concentrations of inhibitor1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Effects of steroid D-ring modification on suicide inactivation and competitive inhibition of aromatase by analogues of androsta-1,4-diene-3,17-dione.
AID53895Catalytic rate constant for time dependent inactivation of Cytochrome P450 19A11996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Time-dependent inactivation of aromatase by 6-alkylandrosta-1,4-diene-3,17-diones. Effects of length and configuration of 6-alkyl group.
AID468984Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 0.3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID53744Catalytic rate constant (Ki) for time-dependent inactivation of Cytochrome P450 19A11996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Time-dependent inactivation of aromatase by 6-alkylandrosta-1,4-diene-3,17-diones. Effects of length and configuration of 6-alkyl group.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID53739Binding affinity was measured on Cytochrome P450 19A11990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Mechanism and inhibition of cytochrome P-450 aromatase.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID53902Michaelis-Menten constant (Km) for human placental cytochrome P450 19A1 binding1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Effects of steroid D-ring modification on suicide inactivation and competitive inhibition of aromatase by analogues of androsta-1,4-diene-3,17-dione.
AID53869Competitive inhibition of binding to human placental aromatase Cytochrome P450 19A11989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Effects of steroid D-ring modification on suicide inactivation and competitive inhibition of aromatase by analogues of androsta-1,4-diene-3,17-dione.
AID53898Apparent inhibition constant (Km) for Cytochrome P450 19A11996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Time-dependent inactivation of aromatase by 6-alkylandrosta-1,4-diene-3,17-diones. Effects of length and configuration of 6-alkyl group.
AID468985Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID1270833Competitive inhibition of human aromatase extracted from placental microsomes in presence of androstenedione2015European journal of medicinal chemistry, Nov-13, Volume: 105Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
AID50906Inhibition of mouse constitutive androstane receptor (mCAR) activity at 10 uM was determined as percent remaining activity2003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Molecular determinants of steroid inhibition for the mouse constitutive androstane receptor.
AID53884Inactivation rate (Ki) for human placental aromatase Cytochrome P450 19A11989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Effects of steroid D-ring modification on suicide inactivation and competitive inhibition of aromatase by analogues of androsta-1,4-diene-3,17-dione.
AID23785Half life period was determined1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Mechanism and inhibition of cytochrome P-450 aromatase.
AID54048Apparent inhibition constant (Ki) Cytochrome P450 19A11996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Time-dependent inactivation of aromatase by 6-alkylandrosta-1,4-diene-3,17-diones. Effects of length and configuration of 6-alkyl group.
AID1811Experimentally measured binding affinity data derived from PDB2001Journal of molecular biology, Jul-06, Volume: 310, Issue:2
Crystal structure of pentaerythritol tetranitrate reductase: "flipped" binding geometries for steroid substrates in different redox states of the enzyme.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2001Journal of molecular biology, Jul-06, Volume: 310, Issue:2
Crystal structure of pentaerythritol tetranitrate reductase: "flipped" binding geometries for steroid substrates in different redox states of the enzyme.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1799735Cholinesterase Inhibition Assay from Article 10.1080/14756360802236393: \\Butyrylcholinesterase inhibitory activity of testosterone and some of its metabolites.\\2009Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 24, Issue:2
Butyrylcholinesterase inhibitory activity of testosterone and some of its metabolites.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (104)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (8.65)18.7374
1990's10 (9.62)18.2507
2000's37 (35.58)29.6817
2010's42 (40.38)24.3611
2020's6 (5.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.85 (24.57)
Research Supply Index4.69 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.93%)5.53%
Reviews3 (2.80%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other103 (96.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]